TEM · earnings call history
Tempus AI Q2 FY26 — Strong Revenue Growth, FDA Approval, and Strategic Acquisition
Read the briefTempus AI Q1 FY26 — Strong Revenue Growth and Increased Full-Year Guidance
Read the briefTempus AI Q4 FY25 — Strong Growth in Diagnostics and Data, Driven by AI Advantage
Read the briefBrowse all US companies on the earnings-call register.